NCT07537634
Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication
StatusCompleted
PhasePhase 4
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 17 words Show 6 more changesShow less
- Trial completed
- Primary completion date changed from estimate of Aug 14, 2026 to Sep 14, 2026
- Study sites: 2 to 1
- Secondary endpoints: details revised at 1 of 4 entries
- Study description expanded, about 6 words
- Publications: details revised at 1 of 2 entries
- Notable Recruitment opened
- Study sites: 1 to 2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
H. pylori Eradication Rate
Timeframe: 4 weeks after completion of 14-day therapy
Secondary (4)
Endoscopic Mucosal Healing rate
Change in dyspeptic symptom severity score
Adverse Events
Compliance to Therapy
Arms and interventions
Vonoprazan-based triple therapy (VAL)Experimental
Participants in this arms will receive vonoprazan based levofloxacin containing triple therapy for 14 days
Esomeprazole-based triple therapy (EAL)Active comparator
Participants in this arms will receive esomeprazole based levofloxacin containing triple therapy for 14 days
Drugs: vonoprazan-based triple therapy (VAL regimen), Esomeprazole-based triple therapy (EAL regimen)
Sites
1 site in 1 country
- Bangabandhu Sheikh Mujib Medical UniversityDhaka, Bangladesh